1. Adelaide Research & Scholarship

Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 21-30 of 45 (Search time: 0.003 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2010Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemiaSaglio, G.; Kim, D.; Issaragrisil, S.; le Coutre, P.; Etienne, G.; Lobo, C.; Pasquini, R.; Clark, R.; Hochhaus, A.; Hughes, T.; Gallagher, N.; Hoenekopp, A.; Haque, A.; Dong, M.; Larson, R.; Kantarjian, H.
2012Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitorsNieborowska-Skorska, M.; Kopinski, P.; Ray, R.; Hoser, G.; Ngaba, D.; Flis, S.; Cramer, K.; Reddy, M.; Koptyra, M.; Penserga, T.; Glodkowska-Mrowka, E.; Bolton, E.; Holyoake, T.; Eaves, C.; Cerny-Reiterer, S.; Valent, P.; Hochhaus, A.; Hughes, T.; Van der Kuip, H.; Sattler, M.; et al.
2010Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)Hughes, T.; Hochhaus, A.; Branford, S.; Muller, M.; Kaeda, J.; Foroni, L.; Druker, B.; Guilhot, F.; Larson, R.; O'Brien, S.; Rudoltz, M.; Mone, M.; Wehrle, E.; Modur, V.; Goldman, J.; Radich, J.
2010Dysregulation of bone remodeling by imatinib mesylateVandyke, K.; Fitter, S.; Dewar, A.; Hughes, T.; Zannettino, A.
2010The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34⁺ cellsEngler, J.; Frede, A.; Saunders, V.; Zannettino, A.; White, D.; Hughes, T.
2010Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNABranford, S.; Hughes, T.
2012BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and managementBranford, S.; Yeung, D.; Prime, J.; Choi, S.; Bang, J.; Park, J.; Kim, D.; Ross, D.; Hughes, T.
2011Front-Line and Salvage Therapies With Tyrosine Kinase Inhibitors and Other Treatments in Chronic Myeloid LeukemiaCortes, J.; Hochhaus, A.; Hughes, T.; Kantarjian, H.
2010Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: A mechanism for improved insulin sensitivity in Type 2 diabetic CML patients?Fitter, S.; Vandyke, K.; Schultz, C.; White, D.; Hughes, T.; Zannettino, A.
2011Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up resultsKantarjian, H.; Giles, F.; Bhalla, K.; Pinilla-Ibarz, J.; Larson, R.; Gattermann, N.; Ottmann, O.; Hochhaus, A.; Radich, J.; Saglio, G.; Hughes, T.; Martinelli, G.; Kim, D.; Shou, Y.; Gallagher, N.; Blakesley, R.; Baccarani, M.; Cortes, J.; le Coutre, P.

Discover